Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Verrica Pharmaceuticals (VRCA) Total Liabilities (2021 - 2025)

Verrica Pharmaceuticals (VRCA) has 5 years of Total Liabilities data on record, last reported at $22.4 million in Q4 2025.

  • For Q4 2025, Total Liabilities fell 65.02% year-over-year to $22.4 million; the TTM value through Dec 2025 reached $22.4 million, down 65.02%, while the annual FY2025 figure was $22.4 million, 65.02% down from the prior year.
  • Total Liabilities reached $22.4 million in Q4 2025 per VRCA's latest filing, down from $57.9 million in the prior quarter.
  • Across five years, Total Liabilities topped out at $67.0 million in Q3 2024 and bottomed at $3.8 million in Q1 2023.
  • Average Total Liabilities over 5 years is $43.8 million, with a median of $47.7 million recorded in 2021.
  • Peak YoY movement for Total Liabilities: crashed 91.79% in 2023, then surged 1608.38% in 2024.
  • A 5-year view of Total Liabilities shows it stood at $47.5 million in 2021, then tumbled by 90.13% to $4.7 million in 2022, then surged by 1218.98% to $61.8 million in 2023, then increased by 3.49% to $64.0 million in 2024, then plummeted by 65.02% to $22.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Total Liabilities were $22.4 million in Q4 2025, $57.9 million in Q3 2025, and $56.6 million in Q2 2025.